• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Colcrys (colchicine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Colcrys (colchicine)

  • Profile

Profile

Contact Information

Contact: Takeda
Website: https://www.takeda.com/en-us/what-we-do/product-portfolio/#section-c

Currently Enrolling Trials

    Show More

    General Information

    Colcrys (colchicine) is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (Autumn crocus, Colchicum autumnale, also known as Meadow saffron). The exact mechanism of action by which Colcrys works is not fully known. However, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1ß. Additionally, colchicine prevents the activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms.

    Colcrys is specifically indicated for the prophylaxis of gout flares, the treatment of acute gout flares when taken at the first sign of a flare and the treatment of familial Mediterranean fever in adults and children four years of age and older.

    Colcrys are supplied as tablets for oral administration. The recommended initial doses are as follows:
    Prophylaxis of Gout Flares:
    For adults and adolescents older than 16 years of age the recommended dose is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.
    Treatment of Gout Flares:
    1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. The maximum recommended dose for treatment of gout flares is 1.8 mg over a 1 hour period. Colcrys may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.
    Familial Mediterranean Fever
    The recommended dose in adults is 1.2 mg to 2.4 mg daily. The dose should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose.
    Recommended Pediatric Dosage
    Prophylaxis and Treatment of Gout Flares:
    Colcrys is not recommended for pediatric use for this indication.
    Familial Mediterranean Fever
    The recommended dosage in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:
    Children 4 - 6 years: 0.3 mg to 1.8 mg daily
    Children 6 - 12 years: 0.9 mg to 1.8 mg daily
    Adolescents older than 12 years: 1.2 mg to 2.4 mg daily

    Mechanism of Action

    Colcrys (colchicine) is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (Autumn crocus, Colchicum autumnale, also known as Meadow saffron). The exact mechanism of action by which Colcrys works is not fully known. However, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1ß. Additionally, colchicine prevents the activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms.

    Side Effects

    Adverse events associated with the use of Colcrys may include, but are not limited to, the following:

    • Diarrhea
    • Pharyngolaryngeal pain
    • Cramping
    • Nausea
    • Abdominal pain
    • Vomiting

    Clinical Trial Results

    The FDA approval of Colcrys for gout was based on two randomized clinical trials. These trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients with gout initiating treatment with urate lowering therapy. In both trials treatment with colchicine decreased the frequency of gout flares. Specific results from one of the trials are as follows:
    This was a multicenter, randomized, double-blind, placebo-controlled, parallel group, 1 week, dose comparison study. The subjects were randomly assigned to three groups: (1) high-dose colchicine (1.2 mg, then 0.6 mg hourly × 6 hours [4.8 mg total]); (2) low-dose colchicine (1.2 mg, then 0.6 mg in 1 hour [1.8 mg total] followed by 5 placebo doses hourly); or (3) placebo (2 capsules, then 1 capsule hourly × 6 hours). Subjects took the first dose within 12 hours of the onset of the flare and recorded pain intensity (11-point Likert scale) and adverse events over 72 hours. Efficacy was measured based on response to treatment in the target joint, using patient self assessment of pain at 24 hours following the time of first dose as recorded in the diary. A responder was one who achieved at least a 50% reduction in pain score at the 24-hour post-dose assessment relative to the pre-treatment score and did not use rescue medication prior to the actual time of 24-hour post-dose assessment. Rates of response were similar for the low-dose treatment group (38%) and the high-dose group (33%) but were higher as compared to the placebo group (16%).

    The FDA approval of Colcrys for familial Mediterranean fever (FMF) was based on three randomized, placebo-controlled studies.
    Study One
    This 6-month crossover study randomized 15 subjects with FMF, 5 of whom discontinued due to study non-compliance. The 10 subjects who completed the study experienced 5 attacks over the course of 90 days while treated with colchicine compared to 59 attacks over the course of 90 days while treated with placebo.
    Study Two
    This 4-month crossover study randomized 22 subjects with FMF, 9 of whom discontinued due to lack of efficacy while receiving placebo or study non-compliance. The 13 subjects who completed the study experienced 18 attacks over the course of 60 days while treated with colchicine compared to 68 attacks over the course of 60 days while treated with placebo.
    Study Three
    This study was discontinued after an interim analysis of 6 of the 11 subjects enrolled had completed the study; results could not be confirmed.

    Approval Date: 2009-10-01
    Company Name: Takeda
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing